Humana price target raised to $320 from $262 at UBS

UBS raised the firm’s price target on Humana (HUM) to $320 from $262 and keeps a Neutral rating on the shares. Managed care organizations broadly raised guidance after stronger-than-expected Q1 results benefited from favorable respiratory trends and seasonal cost patterns, while improved Medicare Advantage rates, steadier ACA exchange enrollment, and modest Medicaid outperformance have boosted confidence in margin recovery despite ongoing cost pressures from specialty drugs, GLP-1s, and behavioral health, the analyst tells investors in a research note.